Tag: vision

Chicago, Illinois, June 16, 2025 (GLOBE NEWSWIRE) -- Mag Mile Capital, Inc. (OTCQB: MMCP) ("Mag Mile", or the "Company") is pleased to announce the successful arrangement of $10.25 million in joint venture equity on behalf of the development team executing an innovative Class A office-to-multifamily conversion project at 111 W. Illinois in the River North neighborhood of Chicago, IL.

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Allied Properties REIT (“Allied”) (TSX:AP.UN) announced today that the Trustees of Allied have declared a distribution of $0.15 per unit for the month of June 2025, representing $1.80 per unit on an annualized basis. The distribution will be payable on July 15, 2025, to unitholders of record as at June 30, 2025.

New York, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Matthew Barry has joined the Company as its Director of Investor Relations.

Midland, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company’s Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company’s Board.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Highway announced today that Mark Ford will join the company as Chief Capacity Officer, a strategic addition to the executive team as the company accelerates growth and advances its long-term vision to redefine trust and identity in freight.